BACKGROUND
This study investigates the synergistic relationship between blood low-density lipoprotein cholesterol (LDL-C) and cerebral beta-amyloid (Aβ) in relation to tau deposition, a key factor in the pathology of Alzheimer’s disease (AD), in ol...
BACKGROUND
This study investigates the synergistic relationship between blood low-density lipoprotein cholesterol (LDL-C) and cerebral beta-amyloid (Aβ) in relation to tau deposition, a key factor in the pathology of Alzheimer’s disease (AD), in older adults across a diverse cognitive spectrum.
OBJECTIVES
To examine whether higher levels of LDL-C in the blood moderate the association of cerebral Aβ with tau deposition in older adults, including those with normal cognition, mild cognitive impairment, and Alzheimer’s disease dementia.
DESIGN
Cross-sectional design.
Setting: The study was conducted as a part of a prospective cohort study. All assessments were done at the Seoul National University Hospital, Seoul, South Korea.
Participants: A total of 136 older adults (aged 55–90 years) with normal cognition, mild cognitive impairment, or Alzheimer’s disease (AD) dementia were included.
MEASUREMENTS
Serum lipid measurements, [11C] Pittsburgh Compound B-positron emission tomography (PET), [18F] AV-1451 PET, and magnetic resonance imaging were performed on all participants.
RESULTS
There was a significant Aβ × LDL-C interaction effect on tau deposition, indicating a synergistic moderation effect of LDL-C on the relationship between Aβ and tau deposition.
Subsequent subgroup analysis showed that the positive association between Aβ and tau deposition was stronger in the higher LDL-C group than in the lower LDL-C group.
In contrast, other lipids, such as total cholesterol, high-density lipoprotein cholesterol, and triglycerides, did not show a similar moderation effect on the relationship between Aβ deposition and tau deposition.
CONCLUSION
Our findings suggest that blood LDL-C synergistically enhances the influence of Aβ deposition on tau pathology, emphasizing the need for greater attention to the role of LDL-C in AD progression.